

Nelfinavir (Mesylate)

Catalog No: tcsc0923



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Size: 1g

Size: 2g



Specifications

CAS No:

159989-65-8

Formula:

$C_{33}H_{49}N_3O_7S_2$

Pathway:

Metabolic Enzyme/Protease;Anti-infection

Target:

HIV Protease;HIV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 25 mg/mL (37.66 mM)

Alternative Names:

AG 1343 Mesylate

Observed Molecular Weight:

663.89


Product Description

Nelfinavir(AG-1341) is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor ($K_i=2$ nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.

IC50 & Target: K_i : 2 nM (HIV-1 protease)^[2].

In Vitro: In vitro exposure (72 hours) of HAECs to NEL (0.25-2 μ g/mL) decreased both basal (2.5-fold) and insulin-induced NO production (4- to 5-fold). NEL suppressed insulin-induced phosphorylation of both Akt and eNOS at serine residues 473 and 1177, respectively. NEL decreased tyrosine phosphorylation of IR- β , IRS-1, and PI3K. Coexposure to troglitazone (TRO; 250 nM) ameliorated the suppressive effects of NEL on insulin signaling and NO production. Coexposure to TRO also increased eNOS expression in NEL-treated HAECs^[1]. Nelfinavir(AG-1341) is a potent enzyme inhibitor ($K_i=2$ nM) and antiviral agent (HIV-1 $ED_{50}=14$ nM). An X-ray cocrystal structure of the enzyme-Nelfinavir(AG-1341) complex reveals how the novel thiophenyl ether and phenol-amide substituents of the inhibitor interact with the S1 and S2 subsites of HIV-1 protease, respectively^[2].

In Vivo: In vivo studies indicate that Nelfinavir(AG-1341) is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!